Searching for predictive blood biomarkers: Misfolded p53 in mild cognitive impairment

Current Alzheimer Research

Volumn 9, Issue 10, 2012, Pages 1191-1197

  Stanga, Serena ^a,c   Lanni, Cristina ^a   Sinforiani, Elena ^b   Mazzini, Giuliano ^a   Racchi, Marco ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Alzheimer's disease (AD); Blood biomarker; Flow cytometry; Mild cognitive impairment (MCI); Positive predictive value; Unfolded p53

Indexed keywords

APOLIPOPROTEIN E4; BIOLOGICAL MARKER; PROTEIN P53;

AGED; ALZHEIMER DISEASE; ARTICLE; ASYMPTOMATIC DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOFLUOROMETRY; DISEASE COURSE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN UNFOLDING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PREDICTIVE VALUE OF TESTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874915777     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512804142886     Document Type: Article

References (44)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-7 (2005).
2. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38: 1688-93 (1988).
3. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Int Med 256: 240-6 (2004).
4. Petersen RC, Knopman DS. MCI is a clinically useful concept. Int Psychogeriatr 18: 394-402 (2006).
5. Amieva H, Letenneur L, Dartigues JF, Rouch-Leroyer I, Sourgen C, D'Alchée-Birée F, et al. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord 18: 87-93 (2004).
6. Busse A, Hensel A, Gühne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 67: 2176-85 (2006).
7. Luis CA, Barker WW, Loewenstein DA, Crum TA, Rogaeva E, Kawarai T, et al. Conversion to dementia among two groups with cognitive impairment. Dement Geriatr Cogn Disord 18: 307-13 (2004).
8. Yaffe K, Petersen RC, Lindquist K, Kramer J. Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord 22: 312-9 (2006).
9. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 63: 674-81 (2006).
10. Lanni C, Racchi M, Mazzini G, Ranzenigo A, Polotti R, Sinforiani E, et al. Conformationally altered p53: a novel Alzheimer's disease marker? Mol Psychiatry 13(6): 641-7 (2008).
11. Lanni C, Racchi M, Stanga S, Mazzini G, Ranzenigo A, Polotti R, et al. Unfolded blood p53 as predictive signature from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 20: 97-104 (2010).
12. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 256: 183-94 (2004).
13. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-8 (1999).
14. Frisoni GB, Geroldi C, Beltramello A, Bianchetti A, Binetti G, Bordiga G, et al. Radial width of the temporal horn: a sensitive measure in Alzheimer's Disease. AJNR 23: 35-47 (2002).
15. Scheltens P, Erkinjunti T, Leys D, Wahlund LO, Inzitari D, del Ser T, et al. White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur Neurol 39: 80-99 (1998).
16. Meplán C, Richard MJ, Hainaut P. Redox signalling and transition metals in the control of the p53 pathway. Biochem Pharmacol 59: 25-33 (2000).
17. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31(3): 545-8 (1990).
18. Busse A, Hensel A, Guhne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 67: 2176-85 (2006).
19. Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 352: 67-9 (2003).
20. Uberti D, Lanni C, Carsana T, Francisconi S, Missale C, Racchi M, et al. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiol Aging 27: 1193-201 (2006).
21. Lanni C, Uberti D, Racchi M, Govoni S, Memo M. Unfolded p53: a potential biomarker for Alzheimer's disease. J Alzheimers Dis 12: 93-9 (2007).
22. Uberti D, Cenini G, Olivari L, Ferrari-Toninelli G, Porrello E, Cecchi C, et al. Over-expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin. J Neurochem 103(1): 322-33 (2007).
23. Lanni C, Nardinocchi L, Puca R, Stanga S, Uberti D, Memo M, et al. Homeodomain interacting protein kinase 2: a target for Alzheimer's beta amyloid leading to misfolded p53 and inappropriate cell survival. PLoS One 5: e10171 (2010).
24. Zhou X, Jia J. P53-mediated G(1)/S checkpoint dysfunction in lymphocytes from Alzheimer's disease patients. Neurosci Lett 468: 320-5 (2010).
25. Alves da Costa C, Checler F. Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism? Cell Signaling 23: 963-968 (2010).
26. Ranganathan S, Bowser R. P53 and cell cycle proteins participate in spinal motor neuron cell death in ALS. Open Pathol J 4: 11-22 (2010).
27. Lanni C, Racchi M, Memo M, Govoni S, Uberti D. p53 at the crossroads between cancer and neurodegeneration. Free Radic Biol Med.: 52(9):1727-33 (2012)
28. Serrano J, Férnandez AP, Martinez-Murillo R, Martinez A. High sensitivity to carcinogenesis in the brain of a mouse model of Alzheimer's disease. Oncogene 29: 2165-2171 (2010).
29. Schmidtke K, Hermeneit S. High rate of conversion to Alzheimer's disease in a cohort of amnestic MCI patients. Int Psychogeriatr 20: 96-108 (2008).
30. Dubois B, Feldman HH, Jacova J, Cummings JL, DeKosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9: 1118-22 (2010).
31. Doody RS, Pavlik V, Massman P, Rountree S, Darby E, Chan W. Predicting progression of Alzheimer's disease. Alzheimers Res Ther 2: 2 (2010).
32. Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res 43: 411-31 (2009).
33. Fotenos AF, Mintun MA, Snyder AZ, Morris JC, Buckner RL. Brain volume decline in aging. Evidence for a relationship between socioeconomic status, preclinical Alzheimer Disease, and reserve. Arch Neurol 65: 113-20 (2008).
34. Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Långström B, Nordberg A. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging. 2010 Aug 3. [Epub ahead of print]
35. Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PIB retention in Alzheimer's disease is a nearly event with complex relationship with csf biomarkers and functional parameters. Curr Alzheimer Res 7: 56-61 (2010).
36. Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 352: 67-9 (2003).
37. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins. Nat Med 13: 1359-62 (2007).
38. Britschgi M, Wyss-Coray T. Blood protein signature for the early diagnosis of Alzheimer disease. Arch Neurol 66: 161-5 (2009).
39. Soares HD, Chen Y, Sabbagh M, Rohrer A, Schrijvers E, Breteler M. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann NY Acad Sci 1180: 56-67 (2009).
40. deToledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA, Leurgans S, et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 25: 1197-203 (2004).
41. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228-34 (2006).
42. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 73: 294-301 (2009).
43. Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Berry-Kravis E, Bennett DA. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment. Neurocase 11: 3-7 (2005).
44. Modrego PJ. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res 3: 161-70 (2006).